

Format for ANSWERING REVIEWERS



March 6, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 7679-review.doc).

Title: Distinct clinical and laboratory characteristics of Latent Autoimmune Diabetes in Adults (LADA) in relation to Type 1 and Type 2 Diabetes Mellitus.

Author: Elena Pipi, Marietta Marketou, Alexandra Tsirogianni

Name of Journal: *World Journal of Diabetes*

ESPS Manuscript NO: 7679

The manuscript has been improved according to the suggestions of reviewers:

1. Dear reviewer, I am most grateful for your remarks.
2. Dear reviewer, I read your remarks with upmost attention and tried to answer accordingly.
Revision has been made according to the suggestions of the reviewer

- (1) Indeed on page 4, line 27 "*I was proposed..*" should be substituted by "*was proposed*".
- (2) To answer your question concerning the right time to start insulin treatment, I would like to draw your attention to the work of Brofy et al Regarding treatment policy in LADA patients, time to insulin treatment is based on clinical judgement, with GAD autoantibodies being of upmost importance^[58]. Interestingly, Stenström *et al.* have suggested that insulin treatment in LADA patients should start as soon as possible^[59]. Since LADA patients are presented not only with gradually developing insulin deficiency, but also with insulin resistance, a unique treatment strategy should be designed, in order to treat hyperglycaemia and to preserve b-cell function^[60].

3. Dear reviewer, I would like to thank you for your most kind remarks.

Thank you again for publishing our manuscript in the *World Journal of Diabetes*

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'Alexandra Tsirogianni', written over a horizontal line.

Dr. Alexandra Tsirogianni, MD, PhD
Director of Department of Immunology-Histocompatibility,
Evangelismos General Hospital,
Athens 10676, Greece